November 11, 2015
Well-matched influenza vaccine prevents P&I hospitalizations and mortality in NH residents
Well-matched influenza vaccine prevents P&I hospitalizations and mortality in NH residents.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
November 11, 2015
Allergan submits Prior Approval Supplement for RESTASIS
Allergan has submitted a Prior Approval Supplement (PAS) for RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, seeking approval of a Multi-Dose Preservative-Free (MDPF) presentation.
November 10, 2015
Inaffit pulls back Natureal light and dark green capsules
Inaffit is voluntarily recalling all lots of Natureal light green and dark green capsules to the consumer level after FDA laboratory testing found Natureal to contain sibutramine.
November 10, 2015
Zenobia recalls Ground Flax Seed Meal due to salmonella
Zenobia Company LLC. of Yonkers, NY is recalling Ground Flax Seed Meal, because they have the potential to be contaminated with Salmonella.
November 9, 2015
Lilly’s ixekizumab shows improvements in signs and symptoms of their disease when compared to placebo
Eli Lilly and Company has announced that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements…
November 9, 2015
Sanofi’s and Regeneron’s study shows improvements in signs and symptoms of rheumatoid arthritis
Sanofi and Regeneron Inc. have announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against…
November 9, 2015
Cosentyx shows no further progression in joint damage in over 80% of PsA
Novartis has announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with…
November 9, 2015
Investigational baricitinib superior to methotrexate monotherapy in achveing clinical remission
Eli Lilly and Company and Incyte Corporation have announced detailed data from the pivotal phase 3 RA-BEGIN study, which show…
November 6, 2015
AstraZeneca buys ZS Pharma
AstraZeneca has entered into a definitive agreement to acquire Nasdaq-listed ZS Pharma, a biopharmaceutical company based in San Mateo, California.
November 6, 2015
FDA approves Genvoya
FDA has approved Genvoya, a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.